课题基金 / 基金详情

Investigation into regulation of immune responses by NK cells and NKT cells

Investigation into regulation of immune responses by NK cells and NKT cells
NK 细胞和 NKT 细胞对免疫反应调节的研究
批准号:
16590411
负责人:
TAKEDA Kazuyoshi
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

TAKEDA Kazuyoshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
I have been analyzed target-recognizing and cytotoxic mechanisms of NK cells and NKT cells to elucidate the possibility to regulate immune responses by these cells and/or their functional molecules.1. TNF-related apoptosis-inducing ligand (TRAIL) is the critical cytotoxic molecule of immature NK cells, and which play critical roles in self-defense of infant mice. We also demonstrated that TRAIL-expressing NK cells in the liver of adult mice are immature NK cells potentially developing into mature NK cells.2. TRAIL is a critical molecule in NK cell mediated tumor surveillance. To utilize TRAIL to tumor therapy, we newly established agonistic monoclonal antibody to DR5 (death-inducing TRAIL receptor) (MD5-1). Treatment with MD5-1 induces tumor rejection of TRAIL-sensitive tumor cells by apoptosis induction, and also induces tumor specific T cell responses, and which results in the rejection of TRAIL-resistant tumor variants.3. We demonstrated that IOCS play a role as costimulatory molecules in NKT cell activation, which augments cytokines production and cytotoxic activity.4. Specific ligand-activated NKT cells temporally internalize inhibitory NK cell receptor (CD94/NKG2), and these NKT cells demonstrate dramatically augmented cytokines production and anti-tumor effects when re-stimulated with α-Galactosylceramide (NKT cell specific ligand). We also demonstrated that this regulation is mediated by IFN-γ. These results suggested that combined therapy of NKT cell specific ligand and/or inhibition of NK cell receptor-mediated signal augments NKT cell mediated anti-tumor effects.5. We reported that TRAIL is expressed on tumor infiltrating T cells in BCG-treated bladder cancers in human, and suggested the possible contribution of TRAIL to therapeutic effect of BCG therapy.6. TWEAK, one of the member of TNF super family as TRAIL, is expressed on macrophages and plays important roles in inhibition of tumor growth and immunological tumor surveillance.
期刊论文(54)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1084/jem.20031457
发表时间: 2004-02-16
期刊: JOURNAL OF EXPERIMENTAL MEDICINE
影响因子: 15.3
作者: [Takeda, K, Yamaguchi, N, Smyth, MJ]
通讯作者: Smyth, MJ
DOI: --
发表时间: 2005
期刊: Uro.Int. 75・1
影响因子: --
作者: [Murat Mehmut, et al.]
通讯作者: et al.
DOI: --
发表时间: 2005
期刊: International Immunology 17
影响因子: --
作者: [田中宏幸, 稲垣直樹, 永井博弌, Rintaro Tsukahara]
通讯作者: Rintaro Tsukahara
ICOS costimulates NKT cell activation.
ICOS 共刺激 NKT 细胞激活。
DOI: --
发表时间: 2005
期刊: BBRC 327・1
影响因子: --
作者: [Akiba, H.et al., Kaneda Hiroshi]
通讯作者: Kaneda Hiroshi
13
    Analysis of cancer microenvironment under the growth control by anti-tumor immune response
    • 批准号:
      18K19483
    • 项目类别:
      Grant-in-Aid for Challenging Research (Exploratory)
    • 资助金额:
      $3.99万
    • 财政年份:
      2018
    • 负责人:
      TAKEDA Kazuyoshi
    • 依托单位:
    Analysis of tumor-rejecting biological reactions induced by tumor specific immune responses
    • 批准号:
      23300355
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $14.14万
    • 财政年份:
      2011
    • 负责人:
      TAKEDA Kazuyoshi
    • 依托单位:
    Genetic assay and study of crop germplasm in and around China (4th)
    • 批准号:
      19255009
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $17.06万
    • 财政年份:
      2007
    • 负责人:
      TAKEDA Kazuyoshi
    • 依托单位:
    Study for genetic diversity of 'uzu'semi-dwarfbarley varieties in evolutionary, morphological and physiological aspects.
    • 批准号:
      16380008
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.98万
    • 财政年份:
      2004
    • 负责人:
      TAKEDA Kazuyoshi
    • 依托单位:
    海外基金